Delta-Fly Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Delta-Fly Pharma şirketinin toplam hissedar öz sermayesi ¥314.0M ve toplam borcu ¥0.0 olup, bu da borç-öz sermaye oranını 0% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla ¥425.0M ve ¥111.0M dir.

Anahtar bilgiler

Borç/özkaynak oranı

JP¥0

Borç

Faiz karşılama oranı	n/a
Nakit	JP¥349.00m
Eşitlik	JP¥314.00m
Toplam yükümlülükler	JP¥111.00m
Toplam varlıklar	JP¥425.00m

Son finansal sağlık güncellemeleri

We're A Little Worried About Delta-Fly Pharma's (TSE:4598) Cash Burn Rate

Sep 06

Is Delta-Fly Pharma (TSE:4598) In A Good Position To Deliver On Growth Plans?

May 22

Recent updates

We're A Little Worried About Delta-Fly Pharma's (TSE:4598) Cash Burn Rate

Sep 06

Is Delta-Fly Pharma (TSE:4598) In A Good Position To Deliver On Growth Plans?

May 22

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: 4598 'nin kısa vadeli varlıkları ( ¥385.0M ) kısa vadeli yükümlülüklerini ( ¥110.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: 4598 şirketinin kısa vadeli varlıkları ( ¥385.0M ) uzun vadeli yükümlülüklerini ( ¥1,000.0K ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: 4598 borçsuzdur.

Borcun Azaltılması: 4598 şirketinin 5 yıl önce borç/öz sermaye oranı 0.3% iken borcu yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: 4598 son raporlanan serbest nakit akışına göre 2 ay boyunca yeterli nakit pistine sahiptir, ancak o zamandan beri ek sermaye artırmıştır.

Tahmini Nakit Akışı: 4598 serbest nakit akışı tahminlerine göre 2 ay boyunca yeterli nakit akışına sahip olması öngörülüyor, ancak o zamandan beri ek sermaye artırdı.

Delta-Fly Pharma Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 6/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

We're A Little Worried About Delta-Fly Pharma's (TSE:4598) Cash Burn Rate

Is Delta-Fly Pharma (TSE:4598) In A Good Position To Deliver On Growth Plans?

Recent updates

Delta-Fly Pharma, Inc. Announces Progress Update of the Phase III Clinical Trial of DFP-14323

Delta-Fly Pharma Inc Provides Update for Expanded Phase I Study of DFP-14927

Delta-Fly Pharma Inc. announces Phase I/II Study of Dfp-10917 and Venetoclax in Aml Patients Begins with Promising Initial Data

We're A Little Worried About Delta-Fly Pharma's (TSE:4598) Cash Burn Rate

Delta-Fly Pharma, Inc. to Report Q2, 2025 Results on Nov 14, 2024

New major risk - Financial position

Delta-Fly Pharma, Inc. Announces Enrollment of Patients in the Phase III Clinical Trial of DFP-14323

Insufficient new directors

Delta-Fly Pharma, Inc. to Report Q1, 2025 Results on Aug 09, 2024

Is Delta-Fly Pharma (TSE:4598) In A Good Position To Deliver On Growth Plans?

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 27, 2024

Delta-Fly Pharma Inc. Receives Notice of Authorization to Conduct the Phase I/II Study of DFP-10917 Combined with Venetoclax

Delta-Fly Pharma Inc. Announces FDA Submission of the Protocol of the Phase I/II Study of DFP-10917 Combined with Venetoclax (VTX) in the AML Patients Treated by VTX in the AML

Delta-Fly Pharma, Inc. to Report Fiscal Year 2024 Results on May 15, 2024

Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323

Delta-Fly Pharma Inc Announces Initiation of Phase III Pivotal Comparative Clinical Trial of DFP-14323

Delta-Fly Pharma, Inc. Provides Update on Interim Analysis Status of Phase III Study of DFP-10917 in Patients with R/R AML

Delta-Fly Pharma, Inc. to Report Q3, 2024 Results on Feb 13, 2024

New major risk - Shareholder dilution

New major risk - Share price stability

Delta-Fly Pharma, Inc. to Report Q2, 2024 Results on Nov 13, 2023

Delta-Fly Pharma, Inc. to Report Q1, 2024 Results on Aug 14, 2023

Third quarter 2023 earnings released: JP¥75.09 loss per share (vs JP¥51.67 loss in 3Q 2022)

Delta-Fly Pharma, Inc. announced that it has received ¥1.300842 billion in funding from Macquarie Group Limited

Delta-Fly Pharma, Inc. announced that it expects to receive ¥1.300842 billion in funding from Macquarie Group Limited

First half 2023 earnings released: JP¥115 loss per share (vs JP¥103 loss in 1H 2022)

Less than half of directors are independent

First quarter 2023 earnings released: JP¥56.83 loss per share (vs JP¥56.58 loss in 1Q 2022)

Delta-Fly Pharma, Inc. to Report Q3, 2023 Results on Feb 14, 2023

Delta-Fly Pharma, Inc., Annual General Meeting, Jun 29, 2022

Less than half of directors are independent

Delta-Fly Pharma, Inc. to Report Fiscal Year 2022 Results on May 13, 2022

New 90-day low: JP¥1,067

New 90-day low: JP¥1,119

New 90-day low: JP¥1,521

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin